Close Concerns

Pediatric clearance expands Stelo’s reach as Dexcom targets growth beyond insulin-treated diabetes The FDA cleared Dexcom’s Stelo on Friday for children aged two years and older. The over-the-counter (OTC) CGM is designed for people not on insulin therapy. Stelo initially launched in the US for people aged 18 and older in August 2024, becoming the first CGM available without a prescription at the time.

Executive Highlights ADA 2026’s day #4 featured data-rich readouts in therapeutics, technology, and disease management. Across several sessions, speakers explored the evolution of incretin‑based therapies, emerging evidence for CGM use outside traditional intensive insulin populations, and a stronger focus on earlier intervention and broad cardiometabolic care.

Executive Highlights ADA 2026 continued strongly in NOLA, with long-anticipated data readouts across incretin-based therapies and AID systems, clinical recommendations, and discussions about the broader diabetes field. Across multiple sessions, including the REIMAGINE symposium, the 2026 Diabetes Year in Review, and the Kelly West Award lecture, speakers advocated for protecting freedom of speech to improve science and health.

Acquisition adds nutrition coaching and dietitian support; redesigned Stelo app introduces AI-powered metabolic health insights Dexcom announced today that it has entered into an agreement to acquire metabolic health platform Nutrisense for an undisclosed amount and simultaneously unveiled a redesigned experience for its Stelo over-the-counter CGM application.

Insulin Therapy Post-hoc analysis of the QWINT program finds comparable hypoglycemia duration between once-weekly efsitora alfa and daily basal insulin In this oral presentation, Dr. Natalie Bellini (University Hospitals) presented a post-hoc analysis of the , evaluating once-weekly insulin efsitora alfa in adults with T2D. Across the phase 3 QWINT program, efsitora alfa showed glycemic efficacy comparable to once‑daily basal insulins with low rates of hypoglycemia.

Each 10% increase in Time in Range linked to 16% lower retinopathy risk DT&T published an analysis today titled, “Association of Continuous Glucose Monitoring Metrics with Incident Diabetic Retinopathy: A Real-World Long-Term Study,” by Dr. Jin Zhou (UCLA) and Dr. Peter Reaven (Phoenix VA Health Care System) et al.

Executive Highlights CES 2026 continued in Las Vegas today, with the Digital Health track seeing a broadening of its topics during Day #2. The discussion around wearables evolved with Mr. Jake Leach chiming in on the benefits of Dexcom CGMs, and panelists increasingly turned an eye to the potential for systemic impacts with policy and investment in AI and food is medicine.

Executive Highlights Day #3 of EASD 2025 was packed with new data across therapy and across tech, and among several powerful award sessions! We kicked off the morning with Prof. Raphael Scharfmann’s (Cochin Institute, France) presentation on pancreatic models and beta cells as he received this year’s honorary 19th Albert Renold Prize. Later in the day, Prof.

[1] As a reminder, T1D is a progressive disease with several stages: stage 1 T1D refers to people with two or more islet autoantibodies and normal glucose level; stage 2 T1D for those with at least two autoantibodies and dysglycemia; and stage 3 for those with clinical diagnosis of T1D. [2]We have always heard the range for TITR for pregnancy begins at 70 mg/dL and were curious to know why this was the TITR range used.

Layoffs primarily affect operations and manufacturing at its San Diego headquarters; company reports R&D capital allocation as goal The San Diego Union-Tribune reported that Dexcom will be laying off 350 workers (~3% of its global workforce), with the majority of the cuts (56%) affecting its San Diego headquarters and 38% of those planned for its operations and manufacturing departments.